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and Bradley T Hymana
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Abstract
Aggregation of amyloid beta peptide into senile plaques and hyperphosphorylated tau protein into
neurofibrillary tangles in the brain are the pathological hallmarks of Alzheimer’s disease. Despite
over a century of research into these lesions, the exact relationship between pathology and
neurotoxicity has yet to be fully elucidated. In order to study the formation of plaques and tangles
and their effects on the brain, we have applied multiphoton in vivo imaging of transgenic mouse
models of Alzheimer’s disease. This technique allows longitudinal imaging of pathological
aggregation of proteins and the subsequent changes in surrounding neuropil neurodegeneration
and recovery after therapeutic interventions.
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1. Introduction
Alzheimer’s disease (AD), first described in 1907, is a devastating neurodegenerative
disorder characterized by dementia and pathologically defined by the presence of 2 types of
abnormal protein aggregates: intracellular neurofibrillary tangles (NFT) and extracellular
senile plaques (1). Plaques are composed largely of aggregated amyloid beta peptide (Aβ)
derived from proteolytic cleavage of amyloid precursor protein (APP), while NFT are
formed of hyperphosphorylated and misfolded tau protein (2). Pathological protein
aggregation is a common feature across the spectrum of neurodegenerative diseases, thus it
is important to elucidate the relationship between protein aggregation and degeneration of
the brain in order to develop therapeutic strategies.
In AD, the presence of plaques is an early occurrence in the disease process and mutations in
amyloid precursor protein and presenilins 1 and 2, proteins involved in cleaving APP to
generate Aβ, can cause rare familial forms of AD strongly implicating amyloid as the
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initiating factor in the disease (3). NFT accumulate and spread through the brain later in the
disease process, however their presence correlates better with cognitive decline, synapse
loss, and neuronal loss than amyloid burden, arguing the importance of NFT in the
degenerative process (4). These post-mortem data implicating amyloid in disease initiation
and NFT in neuronal death are correlative and not definitive since by their nature these
experiments cannot determine the precise timing and order of events. Using transgenic
mouse models that accumulate plaque or tangle pathology, we have developed a method
combining in vivo multiphoton imaging of pathology with viral infections to fill neurons
with fluorophores, proteins postulated to be involved in neurodegeneration, or functional
indicators to study the timing of plaque and tangle formation and the degeneration
associated with them (see outline of the method in figure 1).
2. Materials and Methods
2.1 Animal models
In order to study aggregation of Alzheimer-related proteins, we take advantage of transgenic
mouse models expressing human amyloid precursor protein, presenilin, or tau with
mutations associated with familial forms of AD or frontotemporal dementia. We have used
several plaque-bearing mouse models including Tg2576 mice which express the 695 amino
acid isoform of APP containing the ‘Swedish’ double mutation Lys670-Asn, Met671-Leu
(5), PDAPP mice expressing an APP minigene with the V717F mutation (6), and APP/PS1
mice expressing a mutant human presenilin 1 (DeltaE9) and a chimeric mouse/human APP
with the Swedish double mutation (7). These mice all develop senile plaques but at different
ages and on different strain backgrounds, so investigating aggregation across several models
allows confirmation of the relevance of findings to the disease pathogenesis. We study NFT
formation and toxicity in the rTg4510 mouse model expressing human tau with the P301L
mutation associated with frontotemporal dementia (8). This model has the advantage of
being regulatable – the transgene can be suppressed with doxycycline administration in the
food – allowing investigation of the reversibility of effects of NFT on the brain.
Transgenic mouse models not directly related to Alzheimer’s pathology are also very useful
for imaging the effects of AD pathology on the brain when crossed with AD model mice.
For example, animals transgenic for fluorescent proteins can be used to study the effects of
pathology on neuronal structure (9), mice expressing immediate early genes could be used to
asses the response of neurons to stimulation (10), mice with fluorescent mitochondria could
be used to study the effects of pathology on mitochondrial localization (11), mice with
fluorescent microglia have been used to observe glial changes around plaques (9,12), etc.
All animal work described here conforms to NIH and institutional IACUC regulations.
2.2 Instrumentation
2.2.1 Surgical equipment—For surgery and imaging, the mouse must be anesthetized
and the head stabilized in a stereotaxic device. Since these are long-term experiments, we
are careful not to place the ear bars into the ears of the animal to avoid rupturing the
tympanic membranes which is painful for the animal. Instead ear bars are placed in the
notch on the skull immediately anterior to the ears. For injection of virus into the brain, a
standard stereotaxic frame with a syringe holder and pump are ideal (stereotaxic apparatus -
David Kopf instruments. Tujunga, CA; injector system - Stoelting Co, Wood Dale, IL).
Similarly, for craniotomy and cranial window implantation, standard stereotaxic devices can
be used. For imaging on the microscope, specialized stereotaxic frames mounted on a base
that fits into the microscope stage can be used, or a small steel bar with a screw hole can be
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implanted adjacent to the cranial window and a small screw used to secure the animal onto a
holder mounted on the microscope stage (13).
For cranial window implantation, we use a dissecting scope (for example Zeiss, Stemi SV6)
to visualize the surgical area and use illuminators with light guides (Fiber Light, Dolan-
Jenner Industries, Boxborough, MA). Standard microsurgical tools are used (from Fine
Science Tools and Harlan Tekland).
2.2.2 Multiphoton microscope system—Imaging with two-photon laser excitation
allows penetration of the laser to subcortical areas up to several hundreds of microns deep
(to layer V) without phototoxicity that would be induced by visible light lasers. For in vivo
multiphoton imaging, we have used 2 systems, (1) a BioRad 1024 system mounted on an
upright Olympus BX50WI microscope with a custom built three channel photomultiplier
array and (2) an Olympus Fluoview 1000MPE mounted on an Olympus BX61WI upright
microscope with four photomultiplier detectors. Both systems use a mode-locked tunable
femtosecond pulsed titanium/sapphire laser (Mai Tai, Spectraphysics) for excitation. A 20×
high numerical aperture (0.95) dipping objective is used due to its long working distance and
large light gathering capacity.
2.3 Surgical Procedures
The specialized surgical techniques for in vivo imaging are difficult to replicate based on
written procedures. Several groups around the world specialize in this type of imaging and
regularly train scientists in the surgical techniques. Watt Webb from Cornell and Winfried
Denk at the Max Planck Institute first implemented multiphoton microscopy for imaging
live cells. Other investigators routinely using cranial window implantation and multiphoton
imaging of the brain include Karel Svoboda at Howard Hughes Medical Institute (13), and
Mark Hubener and Tobias Bonhoeffer at the Max Planck Institute (14). There are also video
protocols that are very useful in learning the technique that have been published in the
Journal of Visualized Experiments (15–17).
Before surgical procedures, sterilize the work area and stereotax with 70% ethanol. Surgical
instruments should be sterilized in a bead sterilizer. Prepare sterile PBS on ice and soak gel
foam cut into small squares (2–3mm) in sterile PBS for keeping the skull moist.
2.3.1 Anesthesia—Either injection or inhalant anesthetics may be used for surgery and
repeated imaging of animals, however, several factors should be considered before choosing
an anesthetic regimen. It is important to maintain body temperature near 37C particularly in
tau expressing animals since hypothermia has been shown to enhance tau phosphorylation
(18). Isoflurane, a commonly used inhalant anesthetic is more dangerous to workers than
injectibles (particularly pregnant women) since they are exposed to some amounts of the
anesthetic which is known to have detrimental effects on the developing brain (19). With
that caveat, we have found that isoflurane is a good choice of anesthetic since body
temperature can be maintained, maintenance of anesthesia for imaging can be done with low
levels of anesthetic (below 1% in oxygen), animals recover very quickly from anesthesia,
and we have very low levels of morbidity associated with isoflurane anesthesia compared to
avertin or ketamine/xylazine. We use isoflurane in oxygen administered via a mask that fits
onto the stereotaxic device from a vaporizer set to 3% for induction (in a chamber) then
reduced to 0.5–2% for maintenance of anesthesia (through the mask). Excess isoflurane is
scavenged using a hood system in surgical areas and with a vacuum line on the microscopes
to minimize human exposure.
Ketamine/xylazine (100mg/kg ketamine, 1mg/kg xylazine) administered intraperitoneally
can also be used. If anesthetic depth is too low, top up doses of ketamine (without xylazine)
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can be administered. In both cases, depth of anesthesia is monitored every 5 minutes by toe
pinch response or observing respiration rate. While anesthetized, body temperature is
maintained with homeothermic blankets and monitored with a temperature probe (Harvard
apparatus, Holliston, MA). Animals recover on the heating blanket. If they have been
anesthetized for over 3 hours, a dose of warm, sterile PBS is administered i.p. (300 μL) to
warm and hydrate the mouse during recovery.
2.3.2 Intracortical injections—Injection of adeno-associated virus or lentivirus can be
used to introduce genes of interest including fluorescent markers for anatomical studies (20),
functional markers such as calcium indicators (21), potential therapeutic proteins (22), or
Alzheimer-related proteins such as tau to study aggregation and toxicity (23,24). For this
procedure, biosafety precautions appropriate for the biohazard potential of each virus should
be used, (lab coat, gloves, mask, etc) as outlined in the manual: Biosafety in Microbiological
and Biomedical Laboratories 5th Edition: Center for Disease Control and National Institutes
of Health (25).
Animals are anesthetized and placed in a stereotaxic apparatus (David Kopf instruments.
Tujunga, CA) with an injector system (Stoelting Co, Wood Dale, IL). Body temperature is
maintained with heating pads as described in section 2.3.1. The scalp is shaved then cleaned
with alternating coats of betadyne and isopropyl alcohol. Lidocaine (xylocaine 2%, Willard,
OH) is injected subcutaneously as a local anesthetic. A small incision (approximately 2–
3mm) is made along the midline of the scalp just posterior to the level of the ears and
microdissecting hooks used to hold the skin out to the sides. The periosteum is removed
with cotton tipped applicators and a surgical marker used to mark the sites on the skull for
injection. Any dorsally located cortical region can be targeted, but we typically inject in
primary somatosensory cortex (hind limb) which is accessible from a cranial window of
6mm diameter on the center of the skull. Coordinates of this area are 1mm lateral from the
midline and 0.5mm posterior to the Bregma suture. The skull should remain moist
throughout the procedure using PBS-soaked Transgel™.
A micro drill with 0.45 mm burr tip (VWR) is used to make a burr hole through the skull at
the injection sites (multiple sites can be injected in one sitting, for example bi- lateral
injections into S1). For each virus used, pilot testing will be needed to determine the amount
of virus to inject for a good infection rate. In our hands, AAV with a titer of approximately
1012 viral genomes/mL works with 2 μL of virus injected per site. The virus is loaded into a
10 μL Hamilton syringe (Hamilton Co, Reno, NV) and the needle placed in the first burr
hole until the tip of the needle touches the dura. From this level, the needle is lowered to
0.5mm deeper than the intended target depth. For example, to infect layer V neurons, the
needle is lowered 1.5mm into the cortex. The needle is allowed to rest for 1 minute at this
depth then raised 0.4mm, rest 1 minute and begin injecting the virus at 0.2 μL/min. After all
of the virus is injected, rest 3 minutes, raise the needle half way to the surface (0.55mm),
rest 3 minutes, then withdraw entirely from the cortex. This slow withdrawal of the needle
prevents the virus-containing liquid from following the needle up through the cortex.
Repeat this procedure at all injection sites then suture or staple the skin closed and apply
antibiotic ointment to the wound. Animals recover from anesthesia on a heating pad then are
returned to the home cage. Virus should be allowed to express for several weeks before
cranial window implantation and imaging.
2.3.3 Cranial Window Implantation—To install a cranial window, animals are
anesthetized and placed into a stereotaxic device to stabilize the head. The scalp is shaved,
cleaned and local anesthetic administered as described for injections in section 2.3.2. The
scalp is removed from the dorsal surface of the head with small scissors to expose the entire
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dorsal surface of the skull. Periosteum is removed with several cotton-tipped applicators.
After this stage, the skull should be kept moist with PBS-soaked gel foam except over areas
that are being drilled. With the drill, a shallow circle approximately 6mm in diameter is
lightly scored starting just anterior to Bregma and ending anterior to lambda. The circle is
then drilled through in small segments until the skull is transparent, taking care to keep the
area cool with frequent applications of chilled PBS. Any bleeding in the skull is stopped by
applying gel foam and removing excess liquid with absorbent triangles (Kettenbach,
Eschenburg, Germany). When the entire circle has been drilled, the skull flap is gently
removed with angled forceps exposing the surface of the brain, and PBS-soaked gel foam is
immediately applied to absorb any bleeding resulting from the removal of the skull. If there
is bleeding, clean gel foam is applied frequently and excess liquid absorbed with absorbent
triangles until all liquid absorbed is clear indicating the bleeding has stopped.
If a topical agent is being applied (for example thioflavin S to label neurofibrillary tangles or
a caspase indicator (24,26), dura are resected with fine forceps to allow the dyes to access
the brain. Topical agents are left to incubate on the brain under plastic wrap for 20–30
minutes with a foil cover to protect the area from light. The brain is then rinsed with PBS
before closing the window site.
The craniotomy is permanently sealed by placing a 7 or 8 mm glass coverslip (Warner
Instruments, Hamden, CT) over the site, filling under the coverslip with PBS, then sealing
the coverslip onto the skull with a mixture of dental acrylic (Jet Denture, Lang Dental
Manufacturing, Wheeling, IL) and krazy glue ™ applied with a toothpick. A temporary seal
can also be used (KwikKast, WPI Sarasota, FL) if multiple agents are applied topically in
the same session, for example imaging, applying antibodies to remove soluble amyloid beta,
then re-imaging (27). To use a head stabilizer that is directly attached to the microscope
stage, a small metal bar with a screw hole is cemented adjacent to the cranial window (13).
If imaging is necessary immediately, the animal can be transferred directly to the
microscope after sealing the craniotomy without waking from anesthesia. When topical
agents are not used, it is preferable to allow the animal to recover and heal after craniotomy
for several weeks before imaging to avoid observing any glial activation due to the surgery
(13).
2.4 Imaging
2.4.1 Dyes to label pathology and structures affected by pathology—A key to
multiphoton imaging in vivo is labeling structures of interest with fluorescent reporters to
make them detectable with the technique. As mentioned in section 2.3.2, fluorophores can
be introduced into brain cells using viral infections, and transgenic animal models with
fluorescent reporters can be used for imaging. Fluorophores can also be introduced via
topical application to the surface of the brain or systemic injections as detailed below.
To label amyloid plaques in APP or APP/PS1 transgenic mice, methoxy XO4 (courtesy
William Klunk, Pittsburgh) is injected i.p. approximately 18 hours prior to imaging.
Methoxy XO4 in injected at 3.3 mg/kg, from a 10 mg/mL stock in DMSO dissolved in
cremophor EL (Fluka) and PBS (10 μL methoxy XO4 stock in 20 μL cremophor topped up
with PBS to make 300 μL final volume). PIB can also be used to label plaques (28).
To label tangles, thioflavin S is applied topically at 0.025% in sterile PBS during cranial
window implantation surgery (26) or X34 can be injected 2 hours before imaging in a lateral
tail vein (0.03% X-34 in PBS, gift from Dr. W.E. Klunk) (24). We have also observed NFT
in vivo after i.v. injection of FSB following the method of Velasco et al. (29).
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Markers of structures and physiological processes that can be affected by pathology can also
be used. The detailed methods for all of these will not be included here but in general the
dyes can be introduced by virus or administered topically or via i.p. or i.v. injection as
described in sections 2.3.2 and 2.3.3 and references can be found in table 1.
Some treatments to clear pathology, such as anti Aβ antibodies, can be fluorescently tagged
to allow monitoring of the treatment along with its effects on pathology. These labeled
antibodies are applied topically to the brain at approximately 1 mg/mL during cranial
window implantation (27,30). Of course, unlabelled treatments (drugs, etc) can also be
administered, and the long term effects of the treatments on pathology can be observed.
It is worth noting that reagents which can cross the blood-brain-barrier and be administered
systemically (i.p. or i.v.) are much better than those that must be applied topically onto the
brain at the time of window implantation as they allow repeat imaging over weeks and
months. These also uniformly label the entire cortex whereas topical agents penetrate slowly
and only reach depths of approximately 200 μm. Topical agents can only be applied once,
when the window is installed, since removing the window causes too much damage to the
brain and almost always results in hemorrhage rendering the window useless for imaging.
On the other hand, topical application of dyes and targeted infection with AAV have the
advantage of not affecting the rest of the body thus isolating any effects seen as truly related
to the cortex.
2.4.2 Angiogram—A fluorescent angiogram is useful for finding the same imaging sites
in multiple imaging sessions. Texas Red dextran (50,000 mw, 12.5 mg/mL in PBS) or any
other fluorescently labeled dextran is injected into a lateral tail vein immediately before
imaging. The dye is cleared from the vessels several hours after injection.
2.4.3 Multiphoton imaging—Before imaging, the animal is anesthetized and a ring of
low melting point wax (<52 °C) is applied around the coverslip to make a well for the
dipping objective. The animal is placed either in a stereotaxic frame that fits into the
microscope stage or screwed onto the head stabilizer on the stage using the metal bar
implanted on the skull. The dipping objective is carefully lowered into a well of distilled
water over the window being careful not to touch the objective to the wax ring or glass
coverslip. Epi-fluorescence with a standard UV filter and a mercury lamp is used to focus on
the surface of the brain. Care should be taken to limit the epi-fluorescence exposure to avoid
photobleaching of the fluorescent dyes. Large blood vessels can be seen using epi-
fluorescence as can labeled amyloid plaques, and an approximate imaging site can be chosen
based on these markers.
For multiphoton imaging, the ideal laser excitation wavelength depends on the dyes used.
For methoxy XO4 labeled plaques, thioflavin S labeled tangles, YFP, GFP, fluorescent
indicator of caspase activation (FLICA), Texas red angiogram, and many other
fluorophores, we find 800nm a suitable excitation wavelength. For each dye and
combination of dyes, a scan of excitation wavelengths can be done to determine the best
wavelength. We keep the laser power as low as possible while still detecting the signal to
avoid photobleaching, particularly for repeat imaging experiments. Laser power is increased
slightly as we image deeper into the cortex since photons are lost due to scattering of deep
tissues. Photomultiplier tube gain and offset are adjusted to maximize clarity of signal at the
beginning of experiments then the same settings are used throughout the experiment where
possible. This is essential in studies such as those using the yellow cameleon calcium
indicator which require precise calibration. Generally, a z-stack in 1–5 μm increments
through the area of interest is obtained with an optical zoom of 3–5× using the 20× 0.95 NA
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dipping objective to obtain a final resolution adequate for imaging pathology, cell bodies,
and neurites.
2.4.4 Repeat imaging of the same sites—To re-image the same brain regions to track
protein aggregation, neuronal degeneration, dendritic spine changes, etc., a low resolution
image is taken with optical zoom 1 or 2× of each imaging site during the first imaging
session. Using fiduciary markers such as the angiogram, large plaques, and the pattern of
neurons or cell bodies, the same sites can be found again at 1 or 2× zoom. Stages with
coordinate tracking systems can also be used to find the same sites, although since the
animal might not be in exactly the same position in the stereotax at each imaging session, it
is usually necessary to zero the coordinates on a large marker within each animal such as a
large blood vessel draining into the superior saggital sinus.
2.5 Image analysis
To correct for breathing and heartbeat-induced motion artifacts, image stacks are aligned
using the StackReg ImageJ plugin (Nathional Institutes of Health free software) (31). Other
software can also be used to align and deconvolve images if necessary (for example
autodeblur from AutoQuant). Images from multiple sessions can be aligned and compared to
observe the formation of plaques and tangles and changes in surrounding neurons, dendritic
spines, dystrophic neurites, neurite curvature, glia, reactive oxygen species, etc.
2.6 Troubleshooting
Several technical difficulties can arise with the surgical preparations and multiphoton
imaging methods described here. During and shortly after cranial window implantation,
excessive bleeding can occur resulting in morbidity or windows obscured by blood that
preclude imaging. To minimize bleeding, careful drilling around the window without
breaking the skull is important as is application of absorbent gel foam immediately after
removing the skull flap. Even with clear imaging on the day of window implantation, some
windows become occluded in the weeks after surgery due to thickening of the meninges.
This can sometimes spontaneously recover allowing imaging in subsequent weeks.
Inadequately securing the mouse’s head in the stereotax results in large motion artifacts
during imaging, thus we recommend tightening the ear bars if motion is detected when
imaging small structures such as spines or using the system of securing the mouse by
screwing to a metal bar implanted at the time of window implantation as described in section
2.3.3. A small amount of motion artifact can be compensated for using image stack
alignment and deconvolution.
3. Discussion
We have used the methods described in this paper to investigate the formation of protein
aggregates in AD models and many of their effects on structure and function of the brain as
illustrated by the examples in figure 2. We have determined the time course of formation of
senile plaques, NFT, and deposition of cerebral amyloid angiopathy, feats impossible
without longitudinal in vivo imaging (9,24,32). We observed that both plaques and tangles
can form within 24 hours, a remarkably fast time course that surprised many in the field
since AD is such a slowly progressing disease.
Structural changes around plaques have been observed including formation of dystrophic
neurites, neurite curvature, dendritic spine loss, decreased dendritic spine turnover, and
accumulation of microglia around plaques (9,20,33). We have also observed degenerative
changes associated with plaques such as increased reactive oxygen species (34), altered
calcium dynamics (21,35), and calcineurin activation (22), which are thought to underlie the
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structural changes in neurons surrounding plaques. Several treatments targeting amyloid
plaques and their effects on neurons have been tried and the results observed over time in
vivo including anti-Aβ antibodies to remove soluble and fibrillar Aβ (27,28,36), calcineurin
inhibitors (22), and anti-oxidants (37,38); these treatments ameliorate to some degree the
structural changes in neurites around plaques. These imaging experiments on APP mice
have shown us that plaques form rapidly and precede the degeneration of neurites and
synapses, and that these changes are reversible, lending support to the hypothesis that
amyloid dysregulation and particularly soluble Aβ are early mediators of cognitive decline
in AD that could be targeted therapeutically.
We have also begun to asses functional changes in the brain circuitry and how it is affected
by plaques, including experiments with a CamKIIα-venus construct that is translocated to
dendrites and translated in response to environmental stimulation (39). The function of
neurons and astrocytes has also been observed using calcium imaging with yellow cameleon
ratiometric dye introduced using AAV and Oregon Green Bapta dye introduced via
micropipette injection (21,35). For in vivo imaging, ratiometric dyes to asses function are
important since readouts that depend on intensity are very difficult to calibrate between
animals. Each imaging site may be at slightly different cortical depth resulting in differing
intensity of signal from the same absolute amount of fluorescence since light scattering
means that deeper tissues are dimmer when imaged with the same laser intensity as more
superficial sites. With ratiometric dyes, each image stack has its own internal control in the
denominator of the ratio.
We also observed rapid formation of NFT which was surprisingly preceded by caspase
activation (24). The rTg4510 model is known to undergo substantial neuronal loss as well as
tangle formation (8,40), but cross-sectional studies cannot determine whether NFT-bearing
neurons are the cells that die, or whether neurons without tangles are more likely to die.
Using in vivo imaging, we have seen that caspases are activated and cellular membranes
disrupted before NFT form but that NFT bearing neurons remain intact for many days, much
longer than would be expected if they were dying of apoptosis (24,41). We continue to study
the phenomena of tangle formation and neuronal death in this model using the uniquely
appropriate method of observing neurons over time in the living brain.
In summary, there are many questions regarding protein aggregation and its toxicity in the
AD brain which the method outlined here, in vivo multiphoton imaging, is ideally suited to
address.
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Figure 1.
Schematic of in vivo imaging.
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Figure 2.
Samples of data from in vivo imaging experiments in AD model mice. (a) shows an example
of plaque formation (arrow points to new plaque, red) over 1 week with simultaneous
imaging of YFP expressing neurites (green) and blood vessels (blue). We observe tangle
formation (blue green, arrowhead points to new tangle labeled with thioflavin S in b)
subsequent to caspase activation (red). We have also treated with anti Aβ antibodies (labeled
with a red fluorophore, c), which decorate methoxy XO4 labeled dense cored plaques (blue/
green). Dendritic spines loss has been observed in vivo (green, d) surrounding dense plaques
(blue). Scale bars represent 50 μm (a), 20 μm (b, c), and 10 μm (d).
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Table 1
Table of structures/processes imaged in vivo
Structure or process observed Dye(s)/ transgenes Reference(s)
Senile plaques Thioflavin S, mehtoxy XO4, PIB (28,42–44)
Neurofibrillary tangles Thioflavin S, X34, FSB (24,26,29)
microglia Transgenic GFP microglia (9,12)
Calcium concentration Yellow chameleon, oregon green bapta (21,35)
Mitochondria Transgenic CFP mitochondria (11)
Neurite structure (dendritic spines, dystrophies,
curvature)
Transgenic YFP neurons, AAV injections of GFP, yellow
chameleon
(9,20,34,36,45,46)
Neuronal nuclei Hoescht (24)
Cellular degeneration markers PI, caspase indicators (24,26,41)
Reactive oxygen species H2DCF, Amplex Red (34,47)
Increased neuronal activity/ local translation in
dendrites
CamKII-venus AAV (39)
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